Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Connors

Showing results (711-720 of 808) with videos related to

Pageof 81
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2015
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell TransplantationHaowei Sun, Kerry J Savage, Aly Karsan, et al.
Cancer Discovery|February 2, 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune RecognitionDaisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, et al.
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Thrombosis Research|September 24, 2025
Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trialsLuis Ortega-Paz, Azita H Talasaz, Parham Sadeghipour, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Blood|October 29, 2020
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHCBrett Collinge, Susana Ben-Neriah, Lauren Chong, et al.
British Journal of Haematology|September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvementTarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood|June 29, 2012
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphomaAnamarija M Perry, Teresa M Cardesa-Salzmann, Paul N Meyer, et al.
JAMA Cardiology|June 1, 2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A ReviewBehnood Bikdeli, Farbod Zahedi Tajrishi, Parham Sadeghipour, et al.
Pageof 81

Showing results (711-720 of 808) with videos related to

Sort By:
Pageof 81
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2015
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell TransplantationHaowei Sun, Kerry J Savage, Aly Karsan, et al.
Cancer Discovery|February 2, 2019
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune RecognitionDaisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, et al.
Blood|January 17, 2020
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 studyDavid J Straus, Monika Długosz-Danecka, Sergey Alekseev, et al.
Thrombosis Research|September 24, 2025
Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trialsLuis Ortega-Paz, Azita H Talasaz, Parham Sadeghipour, et al.
The Lancet. Haematology|May 28, 2021
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trialDavid J Straus, Monika Długosz-Danecka, Joseph M Connors, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Blood|October 29, 2020
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHCBrett Collinge, Susana Ben-Neriah, Lauren Chong, et al.
British Journal of Haematology|September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvementTarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood|June 29, 2012
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphomaAnamarija M Perry, Teresa M Cardesa-Salzmann, Paul N Meyer, et al.
JAMA Cardiology|June 1, 2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A ReviewBehnood Bikdeli, Farbod Zahedi Tajrishi, Parham Sadeghipour, et al.
Pageof 81